Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Eastern Cooperative Oncology Group
AstraZeneca
NRG Oncology
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Pfizer
Mashhad University of Medical Sciences
National Cancer Institute (NCI)
Exelixis
AstraZeneca
AstraZeneca
AstraZeneca
Sanofi
Exelixis
Trans Tasman Radiation Oncology Group
Australasian Gastro-Intestinal Trials Group
AstraZeneca
AstraZeneca
Eurofarma Laboratorios S.A.
LEO Pharma
AstraZeneca
UNICANCER
Imunon
UNICANCER
University of Chicago
Novartis
Shanghai Henlius Biotech
Nektar Therapeutics
Trans Tasman Radiation Oncology Group
NSABP Foundation Inc
Inovio Pharmaceuticals
Australasian Gastro-Intestinal Trials Group
Takeda
Hoffmann-La Roche
Blokhin's Russian Cancer Research Center
UroGen Pharma Ltd.
Steba Biotech S.A.
Ipsen
ChineseAMS
UroGen Pharma Ltd.
Steba Biotech S.A.
Novartis
Queensland Centre for Gynaecological Cancer
Symphogen A/S
Amgen